Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Gross Margin (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Gross Margin for 8 consecutive years, with 186.75% as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Gross Margin fell 18251.0% year-over-year to 186.75%, compared with a TTM value of 11.71% through Sep 2024, down 1727.0%, and an annual FY2023 reading of 33.26%, down 4771.0% over the prior year.
  • Gross Margin was 186.75% for Q3 2024 at Avalo Therapeutics, down from 138.7% in the prior quarter.
  • Across five years, Gross Margin topped out at 138.7% in Q4 2023 and bottomed at 186.75% in Q3 2024.
  • Average Gross Margin over 5 years is 13.16%, with a median of 30.92% recorded in 2022.
  • The sharpest move saw Gross Margin soared 12452bps in 2022, then crashed -18251bps in 2024.
  • Year by year, Gross Margin stood at 41.66% in 2020, then plummeted by -125bps to 93.61% in 2021, then soared by 133bps to 30.92% in 2022, then skyrocketed by 349bps to 138.7% in 2023, then crashed by -235bps to 186.75% in 2024.
  • Business Quant data shows Gross Margin for AVTX at 186.75% in Q3 2024, 138.7% in Q4 2023, and 4.24% in Q3 2023.